Therefore, in order to avoid the complications of impaired glucose metabolism, and to broaden the possible clinical indications, we decided to study the molecular mechanism of SGLT2 inhibitors in doxorubicin-induced heart failure. Here, SLC5A2 is linked to heart failure.